Anaptysbio (ANAB) Current Assets (2016 - 2026)

Anaptysbio (ANAB) has 11 years of Current Assets data on file, last reported at $316.1 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 12.94% year-over-year to $316.1 million; the trailing twelve-month figure through Mar 2026 stood at $316.1 million (down 12.94% YoY), and the FY2025 full-year result was $350.2 million, down 18.9% from the prior year.
• Current Assets for Q1 2026 stood at $316.1 million, down from $350.2 million in the prior quarter.
• Across five years, Current Assets topped out at $512.4 million in Q1 2022 and bottomed at $291.9 million in Q2 2025.
• The 5-year median for Current Assets is $428.0 million (2023), against an average of $402.7 million.
• The widest annual swing landed in 2022, when Current Assets surged 32.36%; it then declined 26.31% in 2025.
• A 5-year view of Current Assets shows it stood at $447.2 million in 2022, then slipped by 9.03% to $406.8 million in 2023, then advanced by 6.16% to $431.9 million in 2024, then declined by 18.9% to $350.2 million in 2025, then decreased by 9.75% to $316.1 million in 2026.
• The last three Current Assets figures came in at $316.1 million (Q1 2026), $350.2 million (Q4 2025), and $330.6 million (Q3 2025), per Business Quant data.

Peer Comparison